ATE140387T1 - Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind - Google Patents

Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind

Info

Publication number
ATE140387T1
ATE140387T1 AT92107179T AT92107179T ATE140387T1 AT E140387 T1 ATE140387 T1 AT E140387T1 AT 92107179 T AT92107179 T AT 92107179T AT 92107179 T AT92107179 T AT 92107179T AT E140387 T1 ATE140387 T1 AT E140387T1
Authority
AT
Austria
Prior art keywords
discoloring
omeprazole
layers
core material
pharmaceutical formulations
Prior art date
Application number
AT92107179T
Other languages
German (de)
English (en)
Inventor
Kurt Loevgren
Ake Pilbrant
Mitsuru Yasumura
Satoshi Morigaki
Minoru Oda
Naohiro Ohishi
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26290693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE140387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Application granted granted Critical
Publication of ATE140387T1 publication Critical patent/ATE140387T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92107179T 1986-04-30 1987-04-16 Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind ATE140387T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB08610572A GB2189698A (en) 1986-04-30 1986-04-30 Coated omeprazole tablets
SG154294A SG154294G (en) 1986-04-30 1994-10-21 New pharmaceutical preparation for oral use

Publications (1)

Publication Number Publication Date
ATE140387T1 true ATE140387T1 (de) 1996-08-15

Family

ID=26290693

Family Applications (3)

Application Number Title Priority Date Filing Date
AT93201611T ATE184482T1 (de) 1986-04-30 1987-04-16 Vehikel für die orale verabreichung säurelabiler pharmaka
AT92107179T ATE140387T1 (de) 1986-04-30 1987-04-16 Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind
AT87850127T ATE84215T1 (de) 1986-04-30 1987-04-16 Arzneizubereitung zur oralen anwendung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93201611T ATE184482T1 (de) 1986-04-30 1987-04-16 Vehikel für die orale verabreichung säurelabiler pharmaka

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT87850127T ATE84215T1 (de) 1986-04-30 1987-04-16 Arzneizubereitung zur oralen anwendung.

Country Status (35)

Country Link
US (1) US4786505A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP0247983B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS62258320A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR910004579B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1020852C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR240250A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (3) ATE184482T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1292693C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1810A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD273197A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE3751860T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK169988B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DZ (1) DZ1077A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2006457T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI90393C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2189698A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (4) GR890300058T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (2) HK135294A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP920854B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU196708B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61416B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL82911A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS1917B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT3699B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (2) LV10357B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO174239C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ220096A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH25701A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL151631B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT84785B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU1820837C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG154294G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI8710681A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU46192B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA872378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JPH0737383B2 (ja) * 1988-07-11 1995-04-26 エーザイ株式会社 胃酸分泌抑制剤含有固型製剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
ES2062527T3 (es) * 1989-05-11 1994-12-16 Chugai Pharmaceutical Co Ltd Preparacion oral que puede ser liberada en una region apropiada del intestino.
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
RU2120798C1 (ru) * 1991-11-22 1998-10-27 Проктер энд Гэмбл Фармасьютикалз, Инк. Твердая фармацевтическая композиция для перорального введения
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
GB9223702D0 (en) 1992-11-12 1992-12-23 Lucas Ind Plc Improvements in hydraulic braking systems for vehicles
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW397686B (en) * 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
TW280770B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1995018612A1 (en) * 1994-01-05 1995-07-13 Aktiebolaget Astra A method for treatment of psoriasis, by omeprazole or related compounds
WO1995022962A1 (en) * 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
WO1996001622A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
HUT75775A (en) * 1994-07-08 1997-05-28 Astra Ab Medicament with multiple unit tablated dosage form containing omeprazole
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH10509193A (ja) * 1994-11-21 1998-09-08 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー ビチューメン組成物
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
GB2316342B (en) * 1995-05-09 2000-01-12 Colorcon Ltd Electrostatic coating
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
TR199701323T1 (xx) * 1995-05-09 1998-02-21 Colorcon Limited Farmas�tik alttabakalar�n elektrostatik olarak kaplanmas� i�in toz kaplama kompozisyonu.
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE69729950T2 (de) * 1996-11-06 2005-07-28 Wockhardt Europe Ltd. Arzneimittel-Zuführsystem mit verzögerter Freisetzung für säurelabile Arzneistoffe
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
HUP0100043A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
WO1999059544A2 (en) 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
SI1105105T1 (sl) * 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
ES2222754T3 (es) * 1998-11-18 2005-02-01 Astrazeneca Ab Procedimiento quimico mejorado, y formulacion farmaceutica.
RU2144823C1 (ru) * 1998-11-20 2000-01-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Лекарственное средство, обладающее слабительным действием
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
ES2288876T3 (es) * 1999-10-20 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento para estabilizar compuestos de bencimidazol.
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
GB0002305D0 (en) 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
AU2002314306C1 (en) * 2001-05-30 2008-12-04 Euro-Celtique S.A. Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2163241A1 (en) * 2001-06-01 2010-03-17 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
ATE476957T1 (de) 2001-09-28 2010-08-15 Mcneil Ppc Inc Pharmazeutische zusammensetzung auf fondantbasis
EP2258351B1 (en) 2001-10-17 2013-06-19 Takeda Pharmaceutical Company Limited Granules containing lansoprazole in large amount
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
ES2286408T3 (es) * 2002-03-05 2007-12-01 Astrazeneca Ab Sales de alquilamonio de omeprazol e esomeprazol.
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
WO2003075825A2 (en) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan The method of treating tuberculosis
US20030180358A1 (en) * 2002-03-25 2003-09-25 Stumberger Walter William System and method for affecting the pH state of the contents of the distal bowel in mammals
CA2477841A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab Method of use
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
DE60319707T2 (de) * 2002-08-02 2008-07-17 Ratiopharm Gmbh Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
WO2004035052A1 (ja) * 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20070036851A1 (en) * 2002-12-23 2007-02-15 Deepak Thassu Acid labile drug compositions
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2523218A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
GB2402895B (en) * 2003-06-18 2006-08-23 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
WO2005009410A2 (en) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Pharmaceutical compositions having a swellable coating
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
MXPA06003100A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis de liberacion retardada.
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (en) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd NEW TRANSMUCOSAL ADMINISTRATION SYSTEM
DK1692516T3 (da) * 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
AU2004287373A1 (en) * 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
JP2007517038A (ja) * 2003-12-30 2007-06-28 ドクター レディズ ラボラトリーズ リミテッド 薬学的組成物
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
CA2557634A1 (en) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Stable capsule preparation
BRPI0509148B8 (pt) * 2004-03-22 2021-05-25 Abbott Products Gmbh composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2566655C (en) * 2004-05-25 2013-04-16 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
AU2005257977A1 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
DK1796730T3 (da) * 2004-09-20 2010-11-01 Ltb4 Sweden Ab Stabiliseret leukotrien B4 (LTB4) farmaceutisk middel
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
BRPI0614914A2 (pt) 2005-07-29 2011-04-19 Solvay Pharm Gmbh processos para a fabricação de pó de pancreatina esterilizada
MX2008001558A (es) * 2005-08-15 2008-02-15 Solvay Pharm Gmbh Composiciones farmaceuticas de desprendimiento controlado para farmacos labiles en medio acido.
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
EP1960384A4 (en) 2005-12-05 2010-03-24 Astrazeneca Ab NOVEL PROCESS FOR THE PRODUCTION OF NON-SALINE ESOMEPRAZOLE
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
RU2467740C2 (ru) * 2005-12-28 2012-11-27 Такеда Фармасьютикал Компани Лимитед Твердое лекарственное средство с контролируемым высвобождением
US8486450B2 (en) 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007080601A1 (en) * 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
ES2550035T3 (es) * 2006-01-27 2015-11-04 Adare Pharmaceuticals, Inc. Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
JP5787301B2 (ja) 2006-01-27 2015-09-30 アデア ファーマシューティカルズ，インコーポレイテッド 弱塩基性薬および有機酸を含む薬物送達系
EP1983827A4 (en) 2006-02-01 2013-07-10 Stuart L Weg USE OF ANTIFUNGAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL CONDITIONS
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
KR101784001B1 (ko) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
EP2046334B1 (en) 2006-07-25 2014-05-21 Vecta Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
WO2008047320A2 (en) * 2006-10-17 2008-04-24 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
SI2124884T1 (sl) 2006-12-22 2019-09-30 Ironwood Pharmaceuticals, Inc. Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
JP5966202B2 (ja) * 2007-02-20 2016-08-10 アラガン ファーマシューティカルズ インターナショナル リミテッド 安定な消化酵素組成物
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
RU2013106514A (ru) 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
TW201004954A (en) * 2008-06-30 2010-02-01 Merck & Co Inc Solid dosage formulations of telcagepant potassium
WO2010011232A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
US9220698B2 (en) * 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010098822A1 (en) 2009-02-24 2010-09-02 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
US20130202688A1 (en) * 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN108187033A (zh) 2010-10-01 2018-06-22 阿普塔利斯制药有限公司 肠溶包衣的低强度胰脂肪酶制剂
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
PT2672981T (pt) 2011-02-11 2018-06-21 Zx Pharma Llc Dispersão de partículas de polímero num meio não aquoso
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
HUE026560T2 (hu) 2011-08-08 2016-06-28 Allergan Pharmaceuticals Int Ltd Eljárás emésztõ enzimeket tartalmazó szilárd készítmények feloldódási viselkedésének vizsgálatára
GB201117480D0 (en) * 2011-10-10 2011-11-23 Palikaras George Filter
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
KR102160388B1 (ko) 2012-03-19 2020-09-28 버크 인스티튜트 포 리서치 온 에이징 App 특이적 bace 억제제(asbi) 및 이의 용도
EP2882304A1 (en) 2012-08-07 2015-06-17 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
CN102940611B (zh) * 2012-11-26 2017-02-22 康普药业股份有限公司 一种含有埃索美拉唑镁的肠溶片剂
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
CN105338958A (zh) 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
JP6471100B2 (ja) 2013-02-12 2019-02-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
PT2872123T (pt) * 2013-04-23 2017-03-15 Zx Pharma Llc Composição multiparticulada com revestimento entérico de libertação controlada de óleo de hortelã-pimenta e métodos relacionados
CA2920844A1 (en) 2013-08-09 2015-02-12 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
CA2932662A1 (en) * 2013-12-20 2015-06-25 9286-3620 Quebec Inc. Protein-based enteric coating for oral dosage forms
CN104490840B (zh) * 2013-12-30 2018-09-28 成都迪康药业股份有限公司 泮托拉唑钠肠溶制剂及其制备方法
CN104337788B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 埃索美拉唑钠肠溶制剂及其制备方法
CN104337789B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 雷贝拉唑钠肠溶制剂及其制备方法
KR101658275B1 (ko) 2014-01-20 2016-09-20 대원제약주식회사 에스오메프라졸 함유 소형 의약정제
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
EP3157568A1 (en) 2014-06-19 2017-04-26 Aptalis Pharma Limited Methods for removing viral contaminants from pancreatic extracts
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) * 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
AU2016294734B2 (en) * 2015-07-17 2021-01-28 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
US20190240187A1 (en) * 2015-11-27 2019-08-08 Symrise Ag Oral preparations with omeprazole or pantoprazole
KR20240064009A (ko) 2016-01-08 2024-05-10 더 리전트 오브 더 유니버시티 오브 캘리포니아 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
WO2017197177A1 (en) 2016-05-12 2017-11-16 Buck Institute For Research On Aging Compounds to promote normal processing of app
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL SUBSTANCES
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
JP7557185B2 (ja) 2017-06-23 2024-09-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を調節するｇａｂａの能力の強化
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
EP3723775A4 (en) 2017-12-15 2022-04-13 Solarea Bio, Inc. MICROBIAL COMPOSITIONS AND METHODS OF TREATING TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
EP3735250A4 (en) 2018-01-01 2022-04-13 The Regents Of The University Of California INDUSTRIAL-SCALE SYNTHESIS OF SILICASOMES-TYPE NANOSUPPORTS
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
RU2694527C1 (ru) 2018-02-06 2019-07-16 Шмуэль Борис Левит Комбинация для регенеративной терапии больных сахарным диабетом 1 типа
EP3610860A1 (en) * 2018-08-15 2020-02-19 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Composition of carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose
CN112839635A (zh) 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
WO2020257722A2 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
TW202126301A (zh) * 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
CN114786652A (zh) * 2019-12-11 2022-07-22 赢创运营有限公司 用于治疗或预防疾病的剂型
CN114828833A (zh) * 2019-12-11 2022-07-29 赢创运营有限公司 包含碱剂和肠溶包衣层的剂型
WO2021115649A1 (en) * 2019-12-11 2021-06-17 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
CN114569579B (zh) * 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN114569580B (zh) * 2020-12-02 2024-03-01 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN112919975B (zh) * 2021-04-01 2022-02-11 山东爱福地生物股份有限公司 一种智能调控土壤酸碱度的有机肥的生产工艺
EP4436407A1 (en) 2021-11-22 2024-10-02 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
CN119522229A (zh) 2022-03-04 2025-02-25 瑞瓦吉尼克斯股份有限公司 广谱氨基糖苷及其用途
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
DE1617615A1 (de) * 1966-05-03 1971-03-25 Merck Patent Gmbh Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4382091A (en) * 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
US4716041A (en) * 1984-02-10 1987-12-29 A/S Alfred Benzon Diffusion coated multiple-units dosage form
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685919A (en) * 1985-03-14 1987-08-11 Ngk Spark Plug Co., Ltd. Artificial joint
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production

Also Published As

Publication number Publication date
NO174239C (no) 1994-04-06
EP0496437A2 (en) 1992-07-29
LV10357A (lv) 1995-02-20
FI871913L (fi) 1987-10-31
GR3007434T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-30
GB8610572D0 (en) 1986-06-04
LV10357B (en) 1996-04-20
EP0247983A2 (en) 1987-12-02
ATE84215T1 (de) 1993-01-15
ZA872378B (en) 1987-12-30
PT84785B (pt) 1989-12-29
SG154294G (en) 1995-03-17
EP0567201A3 (en) 1995-06-07
CY1810A (en) 1995-10-20
HU196708B (en) 1989-01-30
HK135294A (en) 1994-12-09
RU1820837C (ru) 1993-06-07
NO871790L (no) 1987-11-02
JP5069807B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-10-01
PH25701A (en) 1991-09-18
KR870009717A (ko) 1987-11-30
JPS62258320A (ja) 1987-11-10
HRP920854A2 (en) 1994-10-31
NO174239B (no) 1993-12-27
ES2135443T3 (es) 1999-11-01
LTIP1683A (en) 1995-07-25
IS3221A7 (is) 1987-10-31
AU601974B2 (en) 1990-09-27
IS1917B (is) 2004-03-15
NZ220096A (en) 1990-04-26
EP0247983B1 (en) 1993-01-07
ATE184482T1 (de) 1999-10-15
DZ1077A1 (fr) 2004-09-13
LV5760B4 (lv) 1997-06-20
PT84785A (en) 1987-05-01
CN1020852C (zh) 1993-05-26
EP0496437A3 (en) 1992-09-02
IL82911A (en) 1991-06-30
DK169988B1 (da) 1995-04-24
DK215887A (da) 1987-10-31
YU46192B (sh) 1993-05-28
CA1292693C (en) 1991-12-03
AR240250A1 (es) 1990-03-30
AU7191287A (en) 1987-11-05
GR3032101T3 (en) 2000-03-31
DE3783394T2 (de) 1993-05-06
PL265416A1 (en) 1988-07-21
EP0567201A2 (en) 1993-10-27
JPH05294831A (ja) 1993-11-09
HK52897A (en) 1997-05-02
GB2189698A (en) 1987-11-04
DE3751860T2 (de) 1996-11-21
DE3783394D1 (de) 1993-02-18
FI90393B (fi) 1993-10-29
PL151631B1 (en) 1990-09-28
FI871913A0 (fi) 1987-04-29
DD273197A5 (de) 1989-11-08
HUT43954A (en) 1988-01-28
YU68187A (en) 1988-12-31
IE61416B1 (en) 1994-11-02
JP2740993B2 (ja) 1998-04-15
RU2095054C1 (ru) 1997-11-10
DE247983T1 (de) 1990-09-27
LT3699B (en) 1996-02-26
ES2091971T3 (es) 1996-11-16
GR3020734T3 (en) 1996-11-30
EP0567201B1 (en) 1999-09-15
CN87103284A (zh) 1987-11-11
EP0496437B1 (en) 1996-07-17
FI90393C (sv) 1994-02-10
SI8710681A8 (en) 1996-10-31
ES2006457T3 (es) 1994-01-01
ES2006457A4 (es) 1989-05-01
NO871790D0 (no) 1987-04-29
EP0247983A3 (en) 1988-10-19
GR890300058T1 (en) 1989-06-22
KR910004579B1 (ko) 1991-07-06
LV5760A4 (lv) 1996-12-20
IE871107L (en) 1987-10-30
HRP920854B1 (en) 1998-12-31
DE3751860D1 (de) 1996-08-22
US4786505A (en) 1988-11-22
DK215887D0 (da) 1987-04-28

Similar Documents

Publication Publication Date Title
ATE140387T1 (de) Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung von omeprazol sind
ATE139692T1 (de) Verwendung von spezifischem kernmaterial und schichten zur herstellung pharmazeutischer formulierungen, die stabil gegen die verfärbung säurelabiler verbindungen sind
PT85616A (de) Aryloxycarbonsaurederivate ihre herstellung und verwendung
DE3768694D1 (de) Kuenstliche haut und deren herstellung.
DE3673047D1 (de) (imidazolyl-4)-piperidine, ihre herstellung und anwendung als heilmittel.
DE3789761D1 (de) Reibungsmaterialien und Herstellung derselben.
ATA30483A (de) Polymerisat- und tensidhaltige präparate, deren herstellung und verwendung
DE10199018I1 (de) Thiazolidindion-Derivate deren Herstellung und Anwendung
FI891591A7 (fi) Ihonhoitokoostumus ja menetelmä sen valmistamiseksi
DE3650339D1 (de) Herstellung von Urandioxid-Material.
DE69307733D1 (de) Calix-[4]-arene-bis-kronen, ihre herstellung und ihre anwendung zur selektiven extrahierung von cäsium und aktiniden
DK668487D0 (da) Kosmetisk praeparat
PT81531A (de) Verfahren zur herstellung von isosilybinfreiem silibinin und araneimittel enthaltend silibinina
IT1172093B (it) Dibenzazepine loro preparazione e loro impiego come medicamenti
DE3789316D1 (de) Herstellung von human-parathyroidhormon.
DE3883108D1 (de) Thermographiematerial und dessen herstellung.
DE3688212D1 (de) Streckblasgeformter behaelter aus polyarylaenthioaether und herstellung davon.
DE3581210D1 (de) Immunotoxin und herstellung.
DE3885384D1 (de) Organosilikonverbindungen, deren Herstellung und Anwendung.
DE3789352D1 (de) Neue biphenylabkömmlinge, deren herstellung und verwendung.
IT1215392B (it) Formulazioni cosmetiche
PT77380B (de) Piperidinderivate ihre herstellung und verwendung
DE3876114D1 (de) Benzodioxol-derivate, diese enthaltende zusammensetzungen und deren verwendung zur herstellung von medikamenten.
DE69128176D1 (de) Herstellung von Fluorphenolen, Fluorhalophenolen, N-Azylfluoranilinen und N-Azylfluorhaloanilinen
PT86606A (pt) Bakterienlysierendes enzymprodukt aus streptomyceten seine herstellung und seine verwendung zur konservierung von kaese

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time